tbuckley/cabot-search huggingface dataset:
Recurrent Angiotensin-Converting Enzyme Inhibitor—Associated Angioedema
Authors: Nancy J. Brown
Journal: JAMA (1997)

<h3>Context.</h3> —Angiotensin-converting enzyme (ACE) inhibitors are associated with an increased risk of angioedema, but the risk of recurrent angioedema if treatment is continued is not known. <h3>Objective.</h3> —To test the hypothesis that the association between ACE inhibitor use and angioedema may not be recognized and to determine characteristics of angioedema associated with continued use of ACE inhibitors. <h3>Design.</h3> —Retrospective cohort study. <h3>Setting.</h3> —Tennessee Medicaid program. <h3>Patients.</h3> —Medicaid enrollees aged 15 years or older who used an ACE inhibitor and had a first documented episode of angioedema between 1986 and 1992 were followed up for recurrent episodes through June 1993. <h3>Measurements and Main Results.</h3> —We previously identified 82 patients with a first confirmed diagnosis of angioedema during 51 752 person-years of ACE inhibitor use in this population (1.6 per 1000 person-years). Among these 82 patients, there were 16 outpatient recurrences of angioedema among 13 patients during 189 patient-years of follow-up (8.5 per 100 patient-years). The rate of angioedema was much higher in users of ACE inhibitors with continued exposure (18.7 per 100 patient-years) than in those whose use of the drug was discontinued (1.8 per 100 patient-years) (<i>P</i>=.001). Review of the medical records for patients taking ACE inhibitors who had recurrent angioedema revealed that physicians attributed angioedema to a number of causes not related to ACE inhibitor use, even after multiple recurrences. <h3>Conclusion.</h3> —Continuing use of ACE inhibitors in spite of angioedema results in a markedly increased rate of angioedema recurrence with serious morbidity.
Correction: More and Better Information to Tackle HIV Epidemics: Towards Improved HIV Incidence Assays
Journal: PLoS Medicine (2011)

PointsN Investments in HIV prevention activities aiming to reduce incidence could be targeted more effectively and efficiently to successful programmes if a quick, easy, valid, and precise method of estimating incidence in populations were available.N Laboratory methods for identifying recent infections have shown promise for this application, although their accuracy has been questioned, and progress and investment in this field has been challenged by technical and marketrelated issues.N A number of activities are now underway to address these factors and several promising new technologies are anticipated in the next few years.
Urologie pratique.
Journal: JAMA (1930)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clearer picture emerging of methotrexate role as part of rheumatoid arthritis treatment
Authors: T. F. Kirn
Journal: JAMA (1988)

SOME RHEUMATOLOGISTS say that gold injections, penicillamine, and antimalarials relieve symptoms for only about 50% of patients with rheumatoid arthritis, in part because efficacy often wanes over time. Thus, for more than a decade, many rheumatologists have been treating patients whose symptoms are intransigent with the cancer drug methotrexate—often with good results, but not without a measure of trepidation because cirrhosis has been attributed to methotrexate in some patients receiving long-term therapy for psoriasis. Three recent studies, presented at the annual meeting of the American Rheumatism Association in Houston, may help allay some fears. While investigators found some evidence of changes in the liver, they found no cirrhosis that they felt should be attributed to methotrexate. "For right now, we're cautiously optimistic," says James E. Brick, MD, assistant professor of medicine at West Virginia School of Medicine, Morgantown. Methotrexate was first used to treat rheumatoid arthritis in the early 1950s,
The legal status of consent to withhold treatment
Authors: Fenella Rouse, Elena Cohen
Journal: JAMA (1987)

<h3>To the Editor.—</h3> We read with interest Judith Areen's<sup>1</sup>excellent article concerning the rights of family members to make decisions to forgo treatment on behalf of incompetent adult patients. Recent important developments in courts and legislatures deserve to be brought to your readers' attention. Just prior to publication of Ms Areen's article, on June 24, 1987, the New Jersey Supreme Court—the first to rule on a right-to-die case (<i>Quinlan</i>1976<sup>2</sup>)— expanded on the family's authority to make treatment-termination decisions without going to court.<sup>3</sup>In<i>In re Jobes</i>, the court held that decisions about a patient's life-sustaining medical treatment are usually best made (when the patient cannot and has not made them) by family members or close friends designated by the patient. "Almost invariably," the court wrote, "the patient's family has an intimate understanding of the patient's medical attitudes and general world view and therefore is in
On Ancient Medicine
Journal: Annals of Internal Medicine (1998)

Medical Writings1 June 1998On Ancient MedicineHippocratesHippocratesSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-11-199806010-00031 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Whoever having undertaken to speak or write on Medicine, have first laid down for themselves some hypothesis to their argument, such as hot, or cold, or moist, or dry, or whatever else they choose … are all clearly mistaken in much that they say.HippocratesOn Ancient MedicineTranslated by Francis AdamsSubmitted by:Rita Khurana, MDBrooklyn, NY 11219Submissions from readers are welcomed. If the quotation is published, the sender's name will be acknowledged. Please include a complete citation, as done for any reference. −The Editor. Author, Article, and Disclosure InformationAffiliations: Submitted by: Rita Khurana, MD; Brooklyn, NY 11219 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 June 1998Volume 128, Issue 11Page: 962 ePublished: 15 August 2000 Issue Published: 1 June 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
THE PROVINCE OF WOMAN IN MEDICINE.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manuscripts Approved for JNCI, May 15 to June 15, 1962
Journal: JNCI Journal of the National Cancer Institute (1962)

Journal Article Manuscripts Approved for JNCI, May 15 to June 15, 1962 Get access JNCI: Journal of the National Cancer Institute, Volume 29, Issue 1, July 1962, Page 225, https://doi.org/10.1093/jnci/29.1.225-a Published: 01 July 1962
Medical schools in the United States and Canada
Journal: JAMA (1993)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manuscripts Approved for JNCI, May 10 to June 10, 1964
Journal: JNCI Journal of the National Cancer Institute (1964)

Journal Article Manuscripts Approved for JNCI, May 10 to June 10, 1964 Get access JNCI: Journal of the National Cancer Institute, Volume 33, Issue 1, July 1964, Page 192, https://doi.org/10.1093/jnci/33.1.192-a Published: 01 July 1964
<i>ROS1</i> Gene Rearrangement Is Identified in NSCLC
Journal: Cancer Discovery (2012)

MAJOR FINDING: ROS1 chromosomal rearrangements define a molecular subtype of NSCLC.ROS1 rearrangements tend to occur in younger, non-smoking NSCLC patients.ROS1-positive NSCLC patients may benefit from crizotinib therapy.
<i>Announcement</i>: Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV — United States, 2016
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

New evidence-based guidelines, Updated Guidelines for Antiretroviral Postexposure Prophylaxis after Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV - United States, 2016, are now available online (http://www.cdc.gov/hiv/guidelines/). The guidelines update and expand the 2005 U.S. Department of Health and Human Services recommendations for clinical care providers regarding nonoccupational postexposure prophylaxis (nPEP) for exposure to human immunodeficiency virus (HIV) outside the health care setting for persons in the United States (1). Materials supporting nPEP guidelines implementation will also be posted online when they become available.
The Concentration-Response Relation between Air Pollution and Daily Deaths
Authors: Joel Schwartz, Ferran Ballester, Marc Saez, Santiago Perez-Hoyos, Juan Bellido, Koldo Cambra, Federico Arribas, Alvaro Canada, Maria Jose Perez-Boillos, Jordi Sunyer
Journal: Environmental Health Perspectives (2001)

Studies on three continents have reported associations between various measures of airborne particles and daily deaths. Sulfur dioxide has also been associated with daily deaths, particularly in Europe. Questions remain about the shape of those associations, particularly whether there are thresholds at low levels. We examined the association of daily concentrations of black smoke and SO(2) with daily deaths in eight Spanish cities (Barcelona, Bilbao, Castellón, Gijón, Oviedo, Valencia, Vitoria, and Zaragoza) with different climates and different environmental and social characteristics. We used nonparametric smoothing to estimate the shape of the concentration-response curve in each city and combined those results using a metasmoothing technique developed by Schwartz and Zanobetti. We extended their method to incorporate random variance components. Black smoke had a nearly linear association with daily deaths, with no evidence of a threshold. A 10 microg/m(3) increase in black smoke was associated with a 0.88% increase in daily deaths (95% confidence interval, 0.56%-1.20%). SO(2) had a less plausible association: Daily deaths increased at very low concentrations, but leveled off and then decreased at higher concentrations. These findings held in both one- and two-pollutant models and held whether we optimized our weather and seasonal model in each city or used the same smoothing parameters in each city. We conclude that the association with particle levels is more convincing than for SO(2), and without a threshold. Linear models provide an adequate estimation of the effect of particulate air pollution on mortality at low to moderate concentrations.
Colestipol and Cholestyramine Resin
Authors: Charles J. Glueck
Journal: JAMA (1972)

Two bile acid-sequestrant anion exchange resins, colestipol (U-26, 597A) and cholestyramine resin (Questran), were given in doses of 20 gm/day for four months each in a 14-month placebo crossover study to 25 patients with familial type II hyperlipoproteinemia. Plasma cholesterol and β-lipoprotein cholesterol were reduced to normal levels in 20 and 22 subjects, respectively, by one or both drugs. Coupled with low cholesterol, low saturated fat, polyunsaturate-rich diet, colestipol and cholestyramine provide parallel and alternative approaches to normalization of cholesterol and β-lipoprotein cholesterol in familial type II hyperlipoproteinemia.
Obituaries
Journal: JAMA (1978)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
REACTIONS OF RABBITS TO NON-HEMOLYTIC STREPTOCOCCI
Authors: C. L. Derick, C. H. Hitchcock, Homer F. Swift
Journal: The Journal of Experimental Medicine (1930)

On page 6, Vol. 52, No. 1, July 1, 1930, in the second explanatory note at the foot of Table I, the plus sign should be a minus sign; i.e., for + = negative reaction read – = negative reaction.
DOMESTIC CORRESPONDENCE.
Authors: W. Thornton Parker
Journal: JAMA (1892)

<h3>To the Editor of the Journal of the American Medical Association:</h3> I desire to call the attention of those who have served as Acting Asst. Surgeons U. S. Army either during or since the War of the Rebellion, to the fact that an Asssociation of Acting Asst. Surgeons U. S. Army was organized in 1868. All past and present Acting Asst. Surgeons are cordially invited to become members, and the addresses of those resident in Chicago, Milwaukee and Cincinnati are especially desired. Circulars can be obtained by addressing the undersigned. Very truly yours, 2220 Wabash Ave., Chicago, Sept. 13, 1892.
PLoS Medicine Issue Image | Vol. 6(8) August 2009
Journal: PLoS Medicine (2009)

In this month's Editorial the PLoS Medicine editors question the nature and effects of shared decision-making on patient care and subsequent treatment. The editors discuss the criteria for when shared decisions between patient and health care provider should be made, how different forms of data presentation can deepen a patient's understanding of possible treatment options, and how certain presentations can also prove unfairly persuasive. Linking to two research articles published this month in PLoS Medicine, both by Cheryl Carling and colleagues (e1000134 and e1000140), the editorial analyzes the best ways for health care providers to be as informative as possible, while maintaining objectivity and a respect for patients' values prior to treatment. Image Credit: Marco Bellucci at flickr.com
Aviation And Physical Fitness
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Persistent parvovirus B19 related anemia of seven years' duration in an HIV‐infected patient: Complete remission associated with highly active antiretroviral therapy
Authors: Eleftherios Mylonakis, Brian P. Dickinson, Maria D. Mileno, Timothy Flanigan, Fred J. Schiffman, Anthony Mega, Josiah D. Rich
Journal: American Journal of Hematology (1999)

A human immunodeficiency virus (HIV)-infected individual was first diagnosed with red blood cell aplasia due to B19 parvovirus infection in late 1989. Over the subsequent seven-year period, he received a total of 119 units of red blood cells (RBCs) and intravenous immunoglobulin every 2–3 weeks. In 1996 combination antiretroviral treatment with a protease inhibitor was initiated. He received four more units during the following two months and then required no more transfusions for the subsequent 24 months of follow-up. His CD4 count progressively increased and DNA polymerase chain reaction for parvovirus B19 became undetectable. Aggressive antiretroviral treatment may effectively diminish transfusion requirements among HIV-infected individuals with pure RBC aplasia resulting from parvovirus B19 infection. Am. J. Hematol. 60:164–166, 1999. © 1999 Wiley-Liss, Inc.
Developmental structure in brain evolution
Authors: Barbara L. Finlay, Richard B. Darlington, Nicholas Nicastro
Journal: Behavioral and Brain Sciences (2001)

First, we clarify the central nature of our argument: our attempt is to apportion variation in brain size between developmental constraint, system-specific change, and "mosaic" change, underlining the unexpectedly large role of developmental constraint, but making no case for exclusivity. We consider the special cases of unusual hypertrophy of single structures in single species, regressive nervous systems, and the unusually variable cerebellum raised by the commentators. We defend the description of the cortex (or any developmentally-constrained structure) as a potential spandrel, and weigh the implications of the spandrel concept for the course of human evolution. The empirical and statistical objections raised in the commentary of Barton are discussed at length. Finally, we catalogue and comment on the suggestions of new ways to study brain evolution, and new aspects of brain evolution to study.
Abstract 3815: Overcoming acquired resistance of Lapatinib in breast cancer with Palbociclib
Authors: Da Eun Jeong, Ahrum Min, Seongyeong Kim, So Hyeon Kim, Yoonjung Park, Yaewon Yang, Kyung-Hun Lee, Seock-Ah Im
Journal: Cancer Research (2019)

Abstract Background : Lapatinib is a dual tyrosine kinase inhibitor that interrupts the ErbB family pathways in many solid tumors. However, the vast majority of patients who initially respond to the treatment will eventually relapse due to acquired resistance. The defects in cell cycle regulation via increased levels of cyclin D-CDK4/6 complex is well known mechanism of the acquired resistance to lapatinib. Thus, CDK4/6 inhibition can be considered as an attractive strategy to overcome lapatinib resistance. In this study, we investigated whether palbociclib, a palbociclib can overcome the resistance to lapatinib by modulating cell cycle regulation. Methods : Acquired resistant SK-BR-3-cells was established by treating lapatinib consistently. The features of lapatinib resistance (LR) cell lines were evaluated by MTT, FACS, Western blotting, qPCR, methylation assay and WES. The antitumor effects of palbociclib in LR cell lines were evaluated through changes in cell cycle progression, proliferative ability and signaling transduction. Results : In LR cell lines, the change of the molecules that were related to G1/S transition of cell cycle was prominent. It was confirmed that cell cycle progression and proliferation were significantly faster in LR cells compared to parental cells. Upregulation of cyclin D1, CDK4, CDK6 was shown in LR cells but cyclin-dependent kinase inhibitor, p16 was downregulated. The increase of Cyclin D1, CDK4, and CDK6 occur at the transcription level, and the epigenetic alteration of CDKN2A was observed. We identified that the palbociclib inhibited the cell cycle progression and reduced the cell viability significantly in LR cells by cell cycle arrest via blocking hyperphosphorylation of Rb. It was also confirmed that these changes resulted in apoptosis. Conclusion : The changes of cell cycle molecules that were related to G1/S transition was observed in LR cells. Upregulation of cyclin D1, CDK4, CDK6, and deficiency in CDKN2A led to the increasing cell cycle progression and prolfieration in LR cells. Therefore, inhibition of these molecules by palbociclib could be an effective strategies for overcoming lapaitnib resistance. Citation Format: Da Eun Jeong, Ahrum Min, Seongyeong Kim, So Hyeon Kim, Yoonjung Park, Yaewon Yang, Kyung-Hun Lee, Seock-Ah Im. Overcoming acquired resistance of Lapatinib in breast cancer with Palbociclib [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3815.